CompletedPhase 2NCT00876863

Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

Studying NON RARE IN EUROPE: Alzheimer disease

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Sangamo Therapeutics
Principal Investigator: Paul S. Aisen, M.D.
Alzheimer's Disease Cooperative Study (ADCS)
Intervention: CERE-110: Adeno-Associated Virus injection Surgery(drug)
Enrollment: 49 enrolled
Eligibility: 55-80 years · All sexes
Timeline: 2008 – 2015

Study locations (10)

University of Alabama, Birmingham, Alabama, United States
University of California, Los Angeles, Los Angeles, California, United States
University of California, San Diego, San Diego, California, United States
Georgetown University, Washington D.C., District of Columbia, United States
Emory University, Atlanta, Georgia, United States
Mount Sinai School of Medicine, New York, New York, United States
Duke University, Durham, North Carolina, United States
Case Western Reserve University, Cleveland, Ohio, United States
Medical University of South Carolina, North Charleston, South Carolina, United States
University of Utah, Salt Lake City, Utah, United States

Collaborators

Alzheimer's Disease Cooperative Study (ADCS)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00876863 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Alzheimer disease →

← Back to all trials